Abstract The human immunodeficiency virus type 1 protease (HIV-1 PR) is a major target for the design of anti-AIDS (acquired immune deficiency syndrome) drugs. Some C 2-symmetric inhibitors have been designed for the C 2-symmetric binding pocket of HIV-1PR. The crystallographic structures reveal that the binding modes are not C 2-symmetric for C 2- symmetric inhibitors binding to PR. In this work, four molecular dynamics (MD) simulations were performed to investigate the binding modes between four C 2-symmetric inhibitors (6 AD, 6AG, 6FD and 6FG) and PR, as well as the stabilities of these inhibitors in the binding pocket. Analysis of the hydrophobic surface of the binding pocket shows that it is necessary to add a polar group to the P1 (benzyl) and P2 (phenyl) groups of the inhibitor 6AD. Analysis of the hydrogen bonds formed between inhibitors and residues (Asp25/Asp25′, Ile50/Ile50′) indicates that the steric structures of the inhibitors are not suitable for the binding pocket. The two increased polar groups of trifluoromethyl and formamido meet the needs of the binding pocket for polar molecules. The inhibitor with both these groups (6FG) has stronger stability than the other three inhibitors, which have only one (6AG and 6FD) or none (6AD) of these groups. The ranking of binding free energies calculated by molecular mechanics-generalized born surface area (MM-GBSA) method agrees well with the experimental data. It is expected that this study will provide theoretical guidance for the design of anti-AIDS drugs targeting HIV-1PR. Figure Left Inhibitor 6AD in the binding pocket of human immunodeficiency virus type 1 protease. Right Differences of free energies for trifluoromethyl and formaminde
human immunodeficiency virus1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/HIV                   

trifluoromethyl               1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Trifluoromethyl       

HIV                           0.99999999858926^^http://www.w3.org/2001/XMLSchema#double             http://dbpedia.org/resource/HIV                   

HIV                           0.99999999858926^^http://www.w3.org/2001/XMLSchema#double             http://dbpedia.org/resource/HIV                   

symmetric                     0.9999999999835154^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Symmetry              

symmetric                     0.9999999999835154^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Symmetry              

P2                            0.9792426037880331^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Propaganda_Due        

protease                      0.9999998850939912^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Protease              

symmetric                     0.9999999999835154^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Symmetry              

steric                        0.9997882481685723^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Steric_effects        

molecules                     0.9999999999781721^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Molecule              

symmetric                     0.9999999999835154^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Symmetry              

inhibitor                     0.8463525972164055^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Protein_folding       

phenyl                        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Phenyl_group          

hydrophobic                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Hydrophobe            

inhibitor                     0.8463525972164055^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Protein_folding       

molecular dynamics            1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Molecular_dynamics    

MD                            0.9267915844810373^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Physician             

trifluoromethyl               1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Trifluoromethyl       

benzyl                        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Benzyl                

HIV-1                         0.999981361816233^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Subtypes_of_HIV       

symmetric                     0.9999999999835154^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Symmetry              

protease                      0.9999998850939912^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Protease              

human immunodeficiency virus  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/HIV                   

crystallographic              0.9999999957909722^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/X-ray_crystallography 

hydrogen bonds                1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Hydrogen_bond         

acquired immune deficiency syndrome1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/HIV/AIDS              

